| Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over (terminated evaluation) NICE TA1188 | — | Terminated (no company submission) | 25 Aug 2026 | Current |
| Rilzabrutinib for treating persistent or chronic immune thrombocytopenia (terminated evaluation) NICE TA1187 | Rilzabrutinib | Terminated (no company submission) | 20 Aug 2026 | Current |
| Lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (terminated evaluation) NICE TA1186 | Lisocabtagene maraleucel | Terminated (no company submission) | 20 Aug 2026 | Current |
| Netarsudil for treating open-angle glaucoma or ocular hypertension (terminated evaluation) NICE TA1180 | — | Terminated (no company submission) | 16 Jul 2026 | Current |
| Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation) NICE TA1179 | — | Terminated (no company submission) | 16 Jul 2026 | Current |
| Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation) NICE TA1168 | Imlunestrant | Terminated (no company submission) | 18 Jun 2026 | Current |
| Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation) NICE TA1163 | — | Terminated (no company submission) | 4 Jun 2026 | Current |
| Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal) NICE TA1154 | Oxybutynin | Terminated (no company submission) | 7 May 2026 | Current |
| Inebilizumab for treating immunoglobulin G4-related disease (terminated evaluation) NICE TA1151 | Inebilizumab | Terminated (no company submission) | 6 May 2026 | Current |
| Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal) NICE TA1144 | Spesolimab | Terminated (no company submission) | 8 Apr 2026 | Current |
| Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal) NICE TA1141 | Nivolumab | Terminated (no company submission) | 17 Mar 2026 | Current |
| Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) NICE TA1137 | Canagliflozin | Terminated (no company submission) | 25 Feb 2026 | Current |
| Baloxavir marboxil for treating and preventing influenza in people 3 weeks and over (terminated evaluation) NICE TA1135 | Baloxavir Marboxil | Terminated (no company submission) | 19 Feb 2026 | Current |
| Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal) NICE TA1132 | Ruxolitinib | Terminated (no company submission) | 17 Feb 2026 | Current |
| Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal) NICE TA1125 | Pembrolizumab | Terminated (no company submission) | 27 Jan 2026 | Current |
| Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal) NICE TA1124 | Concizumab | Terminated (no company submission) | 27 Jan 2026 | Current |
| Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal) NICE TA1123 | Depemokimab | Terminated (no company submission) | 22 Jan 2026 | Current |
| Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal) NICE TA1118 | Entrectinib | Terminated (no company submission) | 7 Jan 2026 | Current |
| Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal) NICE TA1112 | Trastuzumab deruxtecan | Terminated (no company submission) | 19 Nov 2025 | Current |
| Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal) NICE TA1111 | Nintedanib | Terminated (no company submission) | 19 Nov 2025 | Current |
| Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal) NICE TA1105 | — | Terminated (no company submission) | 22 Oct 2025 | Current |
| Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal) NICE TA1104 | Sarilumab | Terminated (no company submission) | 22 Oct 2025 | Current |
| Iptacopan for treating complement 3 glomerulopathy (terminated appraisal) NICE TA1102 | Iptacopan | Terminated (no company submission) | 29 Oct 2025 | Current |
| Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal) NICE TA1100 | Mirabegron | Terminated (no company submission) | 1 Oct 2025 | Current |
| Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal) NICE TA1089 | Sacituzumab Govitecan | Terminated (no company submission) | 13 Aug 2025 | Current |
| Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal) NICE TA1084 | Idecabtagene vicleucel | Terminated (no company submission) | 23 Jul 2025 | Current |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal) NICE TA1083 | Lisocabtagene maraleucel | Terminated (no company submission) | 23 Jul 2025 | Current |
| Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal) NICE TA1082 | Letermovir | Terminated (no company submission) | 23 Jul 2025 | Current |
| Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal) NICE TA1078 | — | Terminated (no company submission) | 25 Jun 2025 | Current |
| Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal) NICE TA1076 | Adagrasib | Terminated (no company submission) | 2 Jul 2025 | Current |
| Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) NICE TA1072 | Tislelizumab | Terminated (no company submission) | 19 Jun 2025 | Current |
| Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) NICE TA1068 | Tislelizumab | Terminated (no company submission) | 29 May 2025 | Current |
| Omaveloxolone for treating Friedreich’s ataxia in people 16 years and over (terminated appraisal) NICE TA1061 | Omaveloxolone | Terminated (no company submission) | 6 May 2025 | Current |
| Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal) NICE TA1058 | Tislelizumab | Terminated (no company submission) | 23 Apr 2025 | Current |
| Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal) NICE TA1052 | — | Terminated (no company submission) | 2 Apr 2025 | Current |
| Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal) NICE TA1047 | Atezolizumab | Terminated (no company submission) | 12 Mar 2025 | Current |
| Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal) NICE TA1032 | Niraparib | Terminated (no company submission) | 22 Jan 2025 | Current |
| Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal) NICE TA1029 | — | Terminated (no company submission) | 15 Jan 2025 | Current |
| Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal) NICE TA1028 | Bimekizumab | Terminated (no company submission) | 15 Jan 2025 | Current |
| Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal) NICE TA1024 | Toripalimab | Terminated (no company submission) | 11 Dec 2024 | Current |
| Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) NICE TA1006 | — | Terminated (no company submission) | 12 Sep 2024 | Current |
| Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) NICE TA994 | Enzalutamide | Terminated (no company submission) | 8 Aug 2024 | Current |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) NICE TA987 | Lisocabtagene maraleucel | Terminated (no company submission) | 10 Jul 2024 | Current |
| Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) NICE TA982 | Baricitinib | Terminated (no company submission) | 13 Jun 2024 | Current |
| Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal) NICE TA980 | Nivolumab | Terminated (no company submission) | 5 Jun 2024 | Current |
| Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) NICE TA978 | Zanubrutinib | Terminated (no company submission) | 29 May 2024 | Current |
| Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) NICE TA976 | Trastuzumab deruxtecan | Terminated (no company submission) | 29 May 2024 | Current |
| Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) NICE TA972 | Sirolimus | Terminated (no company submission) | 22 May 2024 | Current |
| Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) NICE TA969 | — | Terminated (no company submission) | 30 Apr 2024 | Current |
| Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) NICE TA968 | — | Terminated (no company submission) | 25 Apr 2024 | Current |
| Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) NICE TA966 | Pembrolizumab | Terminated (no company submission) | 24 Apr 2024 | Current |
| Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) NICE TA965 | — | Terminated (no company submission) | 28 Mar 2024 | Current |
| Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) NICE TA961 | — | Terminated (no company submission) | 28 Mar 2024 | Current |
| Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) NICE TA960 | Satralizumab | Terminated (no company submission) | 27 Mar 2024 | Current |
| Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) NICE TA945 | Treosulfan | Terminated (no company submission) | 30 Jan 2024 | Current |
| Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) NICE TA941 | Ravulizumab | Terminated (no company submission) | 20 Dec 2023 | Current |
| Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) NICE TA940 | Ravulizumab | Terminated (no company submission) | 20 Dec 2023 | Current |
| Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) NICE TA938 | Dupilumab | Terminated (no company submission) | 7 Dec 2023 | Current |
| Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) NICE TA936 | Idecabtagene vicleucel | Terminated (no company submission) | 30 Nov 2023 | Current |
| Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) NICE TA933 | Tisagenlecleucel | Terminated (no company submission) | 29 Nov 2023 | Current |
| Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) NICE TA932 | Decitabine | Terminated (no company submission) | 23 Nov 2023 | Current |
| Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) NICE TA923 | Tabelecleucel | Terminated (no company submission) | 19 Oct 2023 | Current |
| Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) NICE TA910 | Semaglutide | Terminated (no company submission) | 13 Jul 2023 | Current |
| Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) NICE TA901 | Cemiplimab | Terminated (no company submission) | 20 Jun 2023 | Current |
| Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal) NICE TA899 | Esketamine | Terminated (no company submission) | 6 Jun 2023 | Current |
| Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) NICE TA889 | — | Terminated (no company submission) | 17 May 2023 | Current |
| Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) NICE TA884 | Capmatinib | Terminated (no company submission) | 3 May 2023 | Current |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) NICE TA879 | Trastuzumab deruxtecan | Terminated (no company submission) | 6 Apr 2023 | Current |
| Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal) NICE TA869 | Teclistamab | Terminated (no company submission) | 16 Feb 2023 | Replaced by TA1015 |
| Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) NICE TA867 | Mitapivat | Terminated (no company submission) | 16 Feb 2023 | Current |
| Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) NICE TA859 | Angiotensin II | Terminated (no company submission) | 16 Jan 2023 | Current |
| Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) NICE TA848 | Cemiplimab | Terminated (no company submission) | 1 Dec 2022 | Current |
| Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) NICE TA847 | Mepolizumab | Terminated (no company submission) | 29 Nov 2022 | Current |
| Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) NICE TA846 | Mepolizumab | Terminated (no company submission) | 29 Nov 2022 | Current |
| Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal) NICE TA845 | Mepolizumab | Terminated (no company submission) | 29 Nov 2022 | Current |
| Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) NICE TA844 | Luspatercept | Terminated (no company submission) | 24 Nov 2022 | Current |
| Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) NICE TA843 | Luspatercept | Terminated (no company submission) | 24 Nov 2022 | Current |
| Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal) NICE TA842 | Tisagenlecleucel | Terminated (no company submission) | 22 Nov 2022 | Current |
| Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) NICE TA841 | Carfilzomib | Terminated (no company submission) | 22 Nov 2022 | Current |
| Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids
(terminated appraisal) NICE TA840 | Ruxolitinib | Terminated (no company submission) | 16 Nov 2022 | Current |
| Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal) NICE TA839 | Ruxolitinib | Terminated (no company submission) | 16 Nov 2022 | Replaced by TA1054 |
| Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) NICE TA838 | Potassium Citrate | Terminated (no company submission) | 2 Nov 2022 | Current |
| SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) NICE TA834 | — | Terminated (no company submission) | 12 Oct 2022 | Replaced by TA1045 |
| Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal) NICE TA826 | Vedolizumab | Terminated (no company submission) | 21 Sep 2022 | Current |
| Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) NICE TA822 | Melphalan | Terminated (no company submission) | 14 Sep 2022 | Current |
| Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) NICE TA811 | Duvelisib | Terminated (no company submission) | 27 Jul 2022 | Current |
| Belimumab for treating lupus nephritis (terminated appraisal) NICE TA806 | Belimumab | Terminated (no company submission) | 13 Jul 2022 | Current |
| Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) NICE TA797 | Enfortumab Vedotin | Terminated (no company submission) | 15 Jun 2022 | Current |
| Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal) NICE TA793 | Anifrolumab | Terminated (no company submission) | 8 Jun 2022 | Current |
| TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) NICE TA790 | — | Terminated (no company submission) | 25 May 2022 | Current |
| Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) NICE TA785 | Nivolumab | Terminated (no company submission) | 20 Apr 2022 | Current |
| Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) NICE TA782 | Tagraxofusp | Terminated (no company submission) | 30 Mar 2022 | Current |
| Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) NICE TA774 | Lenalidomide | Terminated (no company submission) | 9 Mar 2022 | Current |
| Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal) NICE TA771 | Daratumumab | Terminated (no company submission) | 9 Feb 2022 | Current |
| Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) NICE TA762 | Olaparib | Terminated (no company submission) | 2 Feb 2022 | Replaced by TA1040 |
| Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) NICE TA750 | Olaparib | Terminated (no company submission) | 8 Dec 2021 | Current |
| Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) NICE TA749 | Liraglutide | Terminated (no company submission) | 1 Dec 2021 | Current |
| NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal) NICE TA745 | — | Terminated (no company submission) | 10 Nov 2021 | Current |
| Baloxavir marboxil for treating acute uncomplicated influenza in people 12 years and over (terminated appraisal) NICE TA732 | Baloxavir Marboxil | Terminated (no company submission) | 6 Oct 2021 | Current |
| Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) NICE TA731 | Vericiguat | Terminated (no company submission) | 29 Sep 2021 | Current |
